Investor Alert: Tyra Biosciences Faces Securities Fraud Investigation by Pomerantz Law Firm
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices involving Tyra Biosciences, Inc. (NASDAQ: TYRA) and certain of its officers and directors on behalf of investors. The investigation follows the release of initial results from a Phase 2 clinical trial for oral dabogratinib in patients with FGFR3-altered bladder cancer. The data showed that while safety was favorable overall, adverse events were reported by participants: 14% at the higher dose and 9% at the lower dose. On this news, Tyra's stock price dropped significantly—$4.72 per share (or 17.66%) to close at $22.01 on September 9, 2026. Pomerantz LLP is a well-known firm in corporate and securities litigation with offices across the U.S., London, Paris, and Tel Aviv.
Tickers: $TYRA
Topics: clinical_trials legal pharmaceuticals